— Know what they know.
Not Investment Advice

ALBO NASDAQ

Albireo Pharma, Inc.
1W: +1.3% 1M: -1.1% 3M: +106.0% 1Y: +60.1% 3Y: +82.3% 5Y: +30.6%
$44.15
Last traded 2023-03-02 — delisted
NASDAQ · Healthcare · Biotechnology · $915.9M mcap · 14M float · 4.16% daily turnover

Balance Sheet Trends

Total Assets
$302M +5.8% ▲
5Y CAGR: +43.5%
Total Liabilities
$126M +21.1% ▲
5Y CAGR: +58.3%
Shareholders Equity
$176M -3.1% ▼
5Y CAGR: +36.6%
Cash & Investments
$248M -1.3% ▼
5Y CAGR: +52.7%
Total Debt
$10M +4.0% ▲
5Y CAGR: +26.6%
Net Debt
-$238M +1.5% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$53M$164M$132M$251M$248M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$53M$164M$132M$251M$248M
Net Receivables$726K$3M$0$0$3M
Inventory$0$0$0$0$194K
Other Current Assets$1M$850K$10M$11M$12M
Total Current Assets$55M$168M$142M$262M$269M
Property, Plant & Equip.$178K$187K$597K$478K$668K
Goodwill & Intangibles$17M$17M$17M$17M$17M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$775K$369K$5M$6M$15M
Total Non-Current Assets$18M$18M$23M$24M$33M
Total Assets$73M$185M$165M$286M$302M
— Liabilities —
Accounts Payable$1M$4M$5M$5M$7M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$7M$8M$14M$20M$39M
Total Current Liabilities$8M$13M$19M$25M$45M
Long-Term Debt$0$0$0$10M$10M
Other Non-Current Liab.$42K$50M$53M$69M$71M
Total Non-Current Liabilities$42K$50M$53M$79M$81M
Total Liabilities$8M$63M$72M$104M$126M
— Equity —
Common Stock$89K$120K$127K$191K$193K
Retained Earnings-$50M-$96M-$159M-$267M-$301M
Accumulated OCI$1M$4M$6M-$9M$1M
Total Stockholders Equity$65M$123M$93M$181M$176M
Total Liabilities & Equity$73M$185M$165M$286M$302M
— Key Metrics —
Total Debt$0$0$0$10M$10M
Net Debt-$53M-$164M-$132M-$242M-$238M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms